Drug Profile
Enadenotucirev - Akamis Bio
Alternative Names: Ad11/Ad3 chimeric group B adenovirus; ColoAd-1; EnAd; Oncolytic Ad11/Ad3 chimeric group B adenovirusLatest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator PsiOxus Therapeutics
- Developer Akamis Bio; Bristol-Myers Squibb; Merck & Co; University of Oxford
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Renal cancer; Urogenital cancer
- No development reported Cancer; Head and neck cancer; Ovarian cancer; Salivary gland cancer; Solid tumours
Most Recent Events
- 26 Feb 2024 Efficacy, pharmacodynamics, pharmacokinetic and adverse events data from a phase I trial in Cancer presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)
- 24 Feb 2023 PsiOxus Therapeutics completes a phase I trial for Colorectal cancer (Metastatic disease; Late-stage disease) in United Kingdom (NCT03916510)
- 05 Jan 2023 PsiOxus Therapeutics is now called Akamis Bio